S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
15 A.I. Trading Opportunities a Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
15 A.I. Trading Opportunities a Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
15 A.I. Trading Opportunities a Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
15 A.I. Trading Opportunities a Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
15 A.I. Trading Opportunities a Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
15 A.I. Trading Opportunities a Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
15 A.I. Trading Opportunities a Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
15 A.I. Trading Opportunities a Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:TYRA

Tyra Biosciences (TYRA) Stock Forecast, Price & News

$13.95
+0.95 (+7.31%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$12.53
▼
$13.95
50-Day Range
$11.99
▼
$16.22
52-Week Range
$4.93
▼
$16.86
Volume
7,400 shs
Average Volume
41,232 shs
Market Capitalization
$593.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Tyra Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.5% Upside
$21.00 Price Target
Short Interest
Bearish
8.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of Tyra Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$414,171 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.39) to ($1.83) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

675th out of 1,010 stocks

Pharmaceutical Preparations Industry

341st out of 494 stocks

See Top Rated MarketRank™ Stocks Here

TYRA stock logo

About Tyra Biosciences (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

TYRA Stock News Headlines

May 25, 2023 | americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.7%
May 24, 2023 | americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $14.45
May 29, 2023 | Stocks To Trade (Ad)
Free A.I. Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
May 23, 2023 | finance.yahoo.com
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
May 22, 2023 | finance.yahoo.com
Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade
May 17, 2023 | americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $12.40
May 8, 2023 | markets.businessinsider.com
Where Tyra Biosciences Stands With Analysts
May 5, 2023 | marketwatch.com
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
May 29, 2023 | Stocks To Trade (Ad)
Free A.I. Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
May 5, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Tyra Bioscience (TYRA)
April 29, 2023 | americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Trading 21.5% Higher
April 15, 2023 | americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Trading Up 8%
April 7, 2023 | americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $15.67
April 6, 2023 | americanbankingnews.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Sells $32,320.00 in Stock
April 1, 2023 | americanbankingnews.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris Sells 2,407 Shares
March 30, 2023 | americanbankingnews.com
Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Sells 2,187 Shares of Stock
March 30, 2023 | americanbankingnews.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Daniel Bensen Sells 8,048 Shares
March 30, 2023 | americanbankingnews.com
Todd Harris Sells 2,779 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock
March 29, 2023 | finance.yahoo.com
Tyra Biosciences to Participate in Upcoming Investor Conferences
March 29, 2023 | americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week High at $16.00
March 29, 2023 | americanbankingnews.com
Q1 2023 EPS Estimates for Tyra Biosciences, Inc. (NASDAQ:TYRA) Boosted by HC Wainwright
March 28, 2023 | americanbankingnews.com
Oppenheimer Research Analysts Cut Earnings Estimates for Tyra Biosciences, Inc. (NASDAQ:TYRA)
March 27, 2023 | finance.yahoo.com
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
March 26, 2023 | americanbankingnews.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells $64,688.00 in Stock
March 26, 2023 | americanbankingnews.com
Tyra Biosciences' (TYRA) Buy Rating Reiterated at HC Wainwright
March 26, 2023 | americanbankingnews.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Expected to Earn Q1 2024 Earnings of ($0.40) Per Share
March 25, 2023 | americanbankingnews.com
Daniel Bensen Sells 3,800 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock
See More Headlines
Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

TYRA Company Calendar

Last Earnings
3/22/2023
Today
5/29/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TYRA
CUSIP
N/A
CIK
1863127
Web
www.tyra.bio
Phone
619-728-4760
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+50.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-55,330,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-19.89%
Return on Assets
-19.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
67.00
Quick Ratio
67.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.11 per share
Price / Book
2.28

Miscellaneous

Outstanding Shares
42,560,000
Free Float
34,731,000
Market Cap
$593.71 million
Optionable
Not Optionable
Beta
0.89

Key Executives

  • Dr. Todd Harris Ph.D. (Age 43)
    Pres, CEO, Sec., Treasurer & Director
    Comp: $612.72k
  • Dr. Ronald V. Swanson Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $536.19k
  • Dr. Hiroomi Tada M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $519.65k
  • Mr. Daniel Bensen (Age 47)
    Co-Founder & COO
  • Lynn Scherm
    Fin. Director
  • Ms. Esther van den Boom CPA (Age 42)
    CPA, Chief Financial Officer
  • Dr. Robert L. Hudkins Ph.D. (Age 67)
    Chief Technology Officer
  • Mr. Ali D. Fawaz J.D.
    Gen. Counsel & Sec.
  • Ms. Sarah Honig
    VP of Corp. Devel. & Strategy
  • Dr. Piyush R. Patel Ph.D. (Age 57)
    Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TYRA Stock - Frequently Asked Questions

Should I buy or sell Tyra Biosciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TYRA shares.
View TYRA analyst ratings or view top-rated stocks.

What is Tyra Biosciences' stock price forecast for 2023?

2 equities research analysts have issued twelve-month price targets for Tyra Biosciences' stock. Their TYRA share price forecasts range from $17.00 to $25.00. On average, they predict the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 50.5% from the stock's current price.
View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts.

How have TYRA shares performed in 2023?

Tyra Biosciences' stock was trading at $7.60 at the start of the year. Since then, TYRA stock has increased by 83.6% and is now trading at $13.95.
View the best growth stocks for 2023 here.

When is Tyra Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our TYRA earnings forecast.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its quarterly earnings data on Wednesday, March, 22nd. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.04.

When did Tyra Biosciences IPO?

(TYRA) raised $100 million in an IPO on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share.

What is Tyra Biosciences' stock symbol?

Tyra Biosciences trades on the NASDAQ under the ticker symbol "TYRA."

Who are Tyra Biosciences' major shareholders?

Tyra Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (7.61%), FMR LLC (7.40%), BlackRock Inc. (1.57%), Geode Capital Management LLC (0.67%), State Street Corp (0.55%) and JPMorgan Chase & Co. (0.45%). Insiders that own company stock include Boxer Capital, Llc, Daniel Bensen, Mva Investors, Llc and Todd Harris.
View institutional ownership trends.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyra Biosciences' stock price today?

One share of TYRA stock can currently be purchased for approximately $13.95.

How much money does Tyra Biosciences make?

Tyra Biosciences (NASDAQ:TYRA) has a market capitalization of $593.71 million. The company earns $-55,330,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How can I contact Tyra Biosciences?

Tyra Biosciences' mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The official website for the company is www.tyra.bio. The company can be reached via phone at 619-728-4760 or via email at aconrad@tyra.bio..

This page (NASDAQ:TYRA) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -